Desmopressin
Also called DDAVP
No single human route established in this referenceProduct label
Research reference
Product label
Desmopressin injection—not nasal/tablet equivalence
For central diabetes insipidus, label daily total 2–4 mcg in one or two SC/IV doses; individualized
Ongoing sodium/fluid review; bleeding-use doses and timing are different
Desmopressin acetate injection product label ↗When results may show
- When change was measured
- Severe low sodium can be life-threatening. Sodium checks, fluid restrictions and interacting-drug review belong to the clinical plan.
- When to assess
- Ongoing sodium/fluid review; bleeding-use doses and timing are different
- Conditions and limitations
- Specified water-balance or bleeding conditions; plans differ. Do not copy nasal or oral amounts into an injection plan, or mistake a daily total for each dose. No automatic starter is configured.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.07× single dose
- Time to steady state
- 15hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Desmopressin acetate injection product labelDo not copy nasal or oral amounts into an injection plan, or mistake a daily total for each dose. No automatic starter is configured.